期刊文献+

索法酮固体分散体的制备及体外溶出特性

Preparation and dissolution property of sofalcone solid dispersion
暂未订购
导出
摘要 目的:制备索法酮固体分散体并考查其体外溶出特性。方法:以PEG2000、PEG4000和PEG6000为载体,采用熔融法制备固体分散体,与物理混合物比较体外溶出度。结果:PEG4000和PEG6000制得的固体分散体的体外溶出度高于PEG2000,均高于物理混合物。载体比例越大,体外溶出越快。结论:以PEG为载体,采用熔融法可制得体外溶出较快的索法酮固体分散体。 OBJECTIVE To prepare sofalcone solid dispersion and to investigate its dissolution rate in vitro. METHODS The sofaleone solid dispersion was prepared by melting method with PEG 2000,PEG 4000 and PEG 6000 as carriers. The dissolution rate in vitro was determined and compared with the simple mixture. RESULTS The dissolution of sofaleone solid dispersion prepared by PEG 4000 or PEG 6000 was faster than those prepared by PEG 2000, which was faster than the simple mixture. The dissolution rate was enhanced with the ratio of carriers increased. CONCLUSION The sofaleone solid dispersion prepared by melting method with PEG as carriers has a rapid dissolutionproperty.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2008年第15期1268-1271,共4页 Chinese Journal of Hospital Pharmacy
关键词 索法酮 固体分散体 溶出速率 聚乙二醇 sofaleone solid dispersion dissolution rate PEG
  • 相关文献

参考文献3

二级参考文献48

  • 1Kuwayama H. Zinc compound is a novel, highly effective triple therapy for eradication of Helicobacter pylori. Gastroenterology 1995; 108: A138.
  • 2Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Effect of genetic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69: 158-168 .
  • 3Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, Nasu J, Okada H, Yokota K, Oguma K, Tsuji T. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol 2001; 16: 723-728.
  • 4Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-meohenyton 4'-hydroxylation status. Clin Pharmacol Ther 1995; 58: 143-154.
  • 5Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990; 161: 626-633.
  • 6Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989; 96: 615-625.
  • 7Graham DY, Lew GM, Evans DG, Evans DJ, Klein PD. Effect of triple therapy (antibiotic plus bismuth) on duodenal ulcer healing. Ann Int Med 1991; 115: 266-269.
  • 8Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-1252.
  • 9Tytgat GN. Review article: treatments that impact favorably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-368.
  • 10Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. European Helicobacter pylori study group (EHPSG). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002; 16: 167-180.

共引文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部